pharmaceutical investing Gemphire Announces Termination of Phase 2a Clinical Trial of Gemcabene in Pediatric NAFLD
pharmaceutical investing Gemcabene Meets Primary Endpoint in INDIGO-1 Study of Severe Hypertriglyceridemia (SHTG) Patients
Cygnus intends to advance resource evaluation and technical studies following successful A$25m placement